FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1325
Abstract: Background Rheumatoid arthritis (RA) is associated with increased neutrophil levels1 and platelet2 counts and decreased lymphocyte levels.1,3 Baricitinib (bari) is a selective and reversible Janus kinase (JAK)1/JAK2 inhibitor in development for patients (pts) with moderate… read more here.
Keywords: eli lilly; lilly company; phase; employee eli ... See more keywords
801-P: Bioequivalence of Insulin Efsitora Alfa (Efsitora) U-500 and U-1000 Formulations
Sign Up to like & getrecommendations! Published in 2025 at "Diabetes"
DOI: 10.2337/db25-801-p
Abstract: Introduction and Objective: Background: Efsitora is a novel basal insulin designed for once-weekly administration. The U-1000 formulation (1000 Units/mL) is an alternate dose strength of efsitora that provides an option for patients with diabetes who… read more here.
Keywords: eli lilly; insulin; lilly company; employee eli ... See more keywords
882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
Sign Up to like & getrecommendations! Published in 2025 at "Diabetes"
DOI: 10.2337/db25-882-p
Abstract: Introduction and Objective: Eloralintide (Elora; LY3841136) is a potent, long acting once weekly (QW) amylin receptor agonist under development for obesity. Unlike other amylin agonist molecules (e.g. Cagrilintide), it is designed to have minimal calcitonin… read more here.
Keywords: eli lilly; obesity; lilly company; employee eli ... See more keywords